Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
Frank Weinz, DVT Spezialist at Arjo, shared on LinkedIn:
”State-of-the-art thromboembolism prophylaxis with the IPK Flowtron ACS900 system from Arjo!
The Flowtron ACS900 is a sophisticated system for VTE (venous thromboembolism) prophylaxis that provides compression therapy to improve blood circulation and prevent thrombosis in clinical settings.
It provides a safe, efficient, and measurable solution for patient treatment—a key aspect in reducing complications such as perioperative thrombosis.
Patient safety
The Flowtron ACS900 uses controlled and intermittent compression to reduce the risk of blood clots.
It is designed so that compression applied to the extremities from distal to proximal with an optimal pressure gradient exerts optimal pressure, thereby significantly minimizing the risk of thrombosis.
This is particularly important in the operating room setting, where patients lie still for long periods of time and the risk of thrombosis and pulmonary embolism is higher.
Compliance
A key feature of the Flowtron ACS900 is that it promotes compliance among both patients and medical staff.
The easy-to-use devices ensure that the therapy is applied regularly and correctly.
Clinical practice has shown that the surgical team appreciates this system thanks to its user-friendliness and effectiveness, which leads to improved therapeutic success.
Measurability and clinical effectiveness
A key advantage of the Flowtron ACS900 compared to other systems, such as the SCD 700, is the ability to directly monitor and document the therapy and its application.
The device provides measurability of compression therapy, allowing medical staff to clearly understand the effectiveness of the treatment.
Efficiency in the operating room
The Flowtron ACS900 from Arjo enables optimized treatment during surgery. Intermittent pneumatic compression increases venous return of venous blood, significantly reducing the risk of stasis.
The Flowtron ACS900 takes over complete thrombosis prophylaxis during use. This reduces the workload for nursing staff, leading to greater efficiency and more effective work in everyday clinical practice.
Evidence-based VTE prevention
The Flowtron ACS900 is based on evidence-based studies that confirm its effectiveness in preventing VTE.
This means that it is not only a functional system for everyday clinical use, but also a device that can demonstrate scientifically proven results, thereby inspiring confidence among doctors and nursing staff.
The Flowtron ACS900 from Arjo offers a state-of-the-art solution for efficient VTE prophylaxis.
It promotes patient safety, ensures compliance during use, and enables measurable, clinically proven therapy.”
Stay updated with Hemostasis Today.
-
Oct 13, 2026, 15:30Sally Mandour: Methemoglobinemia When Hemoglobin Cannot Carry Oxygen
-
Oct 13, 2026, 15:21Renel Tique: Advancing Hemophilia Care Through Global Collaboration and Clinical Innovation
-
Oct 13, 2026, 15:08Anastasia Chatzistamati: Unilateral Adrenal Haemorrhage in Primary Antiphospholipid Syndrome
-
Oct 13, 2026, 15:08Yousma Khan: Hematology Practical Series Day 11 Reticulocyte Count and Its Role in Anemia Diagnosis
-
Oct 13, 2026, 14:56Manal Rayyan: Multidisciplinary Collaboration in Rare Bleeding Disorders – Reflections from Abu Dhabi
-
Oct 13, 2026, 14:54Kalyan Roy: Understanding Blood Transfusion Sets for Safe Clinical Administration
-
Oct 13, 2026, 14:52Chedia Aroua: When Pharmacokinetics Meets Geophysics – Finding Unlikely Connections in Hemophilia Care
-
Oct 13, 2026, 14:47Mehmet Can Uğur: Honored by the Presence and Mentorship of Prof. Dargaud at Our Congress
-
Oct 13, 2026, 14:40Cheryl Loetscher: This Day in Drug Discovery – Wakix and H3 Receptor Inverse Agonism in Narcolepsy